10-K: Clene Inc. Reports 2024 Results, Outlines Path to Potential Accelerated Approval for CNM-Au8 in ALS

Clene Inc. details its 2024 financial results and provides an update on its regulatory strategy for CNM-Au8, its lead drug candidate for ALS.

Summary

• Clene Inc. reported its 2024 financial results, highlighting ongoing efforts to advance CNM-Au8, its lead drug candidate, for the treatment of ALS, MS, and PD.
• The company is pursuing a potential accelerated approval pathway for CNM-Au8 in ALS, based on additional data from ongoing Expanded Access Programs (EAPs).
• The FDA has recommended investigating additional data from ongoing EAPs to substantiate the effect of CNM-Au8 on neurofilament light (NfL) decline.
• A confirmatory Phase 3 trial, RESTORE-ALS, is planned to commence with participant enrollment beginning prior to the submission of the NDA.
• The company is also conducting a second dosing cohort of REPAIR-MS, a Phase 2 clinical trial in non-active progressive MS patients, with topline results expected in the second half of 2025.
• Clene has a limited operating history and has incurred significant net losses and net operating cash outflows since its inception.
• The company's ability to continue as a going concern is dependent on obtaining sufficient funding to finance its operations.
• Clene's cash, cash equivalents, and marketable securities totaled $12.2 million as of December 31, 2024.
• The company plans to raise additional funding through equity financing, debt financing, licensing or collaboration arrangements, and utilization of existing at-the-market facility and equity purchase agreement.
• Clene identified material weaknesses in its internal control over financial reporting.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments regarding the regulatory pathway for CNM-Au8 and ongoing clinical trials, the company's financial situation and material weaknesses in internal control over financial reporting raise concerns.

Positives

• The FDA has provided guidance on a potential path to meet the regulatory standard for substantial evidence of effectiveness supporting accelerated approval for CNM-Au8 in ALS.
• A confirmatory Phase 3 trial, RESTORE-ALS, is planned to commence with participant enrollment beginning prior to the submission of the NDA.
• The company is also conducting a second dosing cohort of REPAIR-MS, a Phase 2 clinical trial in non-active progressive MS patients, with topline results expected in the second half of 2025.

Negatives

• Clene has a limited operating history and has incurred significant net losses and net operating cash outflows since its inception.
• The company's ability to continue as a going concern is dependent on obtaining sufficient funding to finance its operations.
• Clene identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on obtaining sufficient funding to finance its operations, which may not be available on acceptable terms, or at all.
• A failure to obtain this necessary capital when needed could force the company to delay, limit, reduce, or terminate its drug development or commercialization efforts.
• The company identified material weaknesses in its internal control over financial reporting, which could lead to inaccuracies in financial statements and impair the ability to comply with reporting requirements.
• There is significant uncertainty associated with the company's drug candidates and their viability as a commercial product.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The price of the company's Common Stock may be volatile.

Future Outlook

Clene plans to pursue a potential accelerated approval pathway for CNM-Au8 in ALS, based on additional data from ongoing Expanded Access Programs (EAPs), and to commence a confirmatory Phase 3 trial, RESTORE-ALS, with participant enrollment beginning prior to the submission of the NDA. The company is also conducting a second dosing cohort of REPAIR-MS, a Phase 2 clinical trial in non-active progressive MS patients, with topline results expected in the second half of 2025.

Industry Context

The treatment landscape for neurodegenerative diseases, particularly ALS, MS, and PD, remains challenging, with limited disease-modifying therapies available. Clene is positioning CNM-Au8 as a potential first-in-class nanotherapeutic with unique catalytic mechanisms of action to address the underlying pathophysiology of these diseases.

Comparison to Industry Standards

• Current ALS treatment therapies, such as riluzole and edaravone, have limited disease-modifying effects, extending lifespan by only a few months or slowing functional decline in a small subset of patients.
• Tofersen, a treatment for SOD1-ALS, addresses only a small fraction of all ALS cases.
• Unlike current immunomodulating DMTs for MS, CNM-Au8 is believed to directly support neuroprotection and remyelination by improving cellular energy metabolism, reducing harmful ROS, and inducing protective heat shock protein mechanisms.
• Current therapies for PD are limited to symptomatic treatment, such as dopamine agonists, COMT and MAO-B inhibitors, and deep brain stimulation, without preventing the progressive degeneration of dopaminergic neurons.

Related Party Transactions

• The company has entered into a note purchase agreement with related parties, including an entity controlled by a member of the board of directors, 4Life, and an entity controlled by the chairman of 4Life who is also a board member of a subsidiary of Clene.

Stakeholder Impact

• The company's ability to continue as a going concern and advance its drug candidates has a significant impact on shareholders, employees, and patients with neurodegenerative diseases.

Next Steps

• Complete NfL biomarker analyses from ongoing FDA-authorized compassionate-use EAPs.
• Meet with the FDA in the first half of 2025 to review and finalize the statistical analysis plan for the EAP NfL biomarker analyses.
• Provide survival pharmacometric modeling analyses of NfL and related disease-specific biomarkers linked to clinical survival benefit and clinical changes from Phase 2 trial data.
• Provide analyses of additional ALS-specific biomarkers to support the pharmacodynamic activity of CNM-Au8 for treatment of ALS.
• Commence a confirmatory Phase 3 trial, RESTORE-ALS, with participant enrollment beginning prior to the submission of the NDA.
• Meet with the FDA in an end of Phase 2 meeting in the second half of 2025.

Key Dates

Keywords

CNM-Au8, ALS, MS, Parkinsons Disease, Clinical Trials, FDA, Accelerated Approval, NfL, RESTORE-ALS, REPAIR-MS, Expanded Access Program, Financial Results, Biotechnology, Pharmaceutical